poeder voor oplossing voor infusie clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedHuman Pharmacology (Phase I)- Other
Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study
This study looks at how much of a medicine called AmBisome, given as a mist you breathe in, reaches the lungs. It aims to find the best dose for treating a fungal lung infection called chronic pulmonary aspergillosis, while also checking for any side effects.
For: Chronic pulmonary aspergillosisNetherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
This study looks at a new medicine called TCD601 (siplizumab) for people who have recently had a kidney transplant. It compares TCD601 to a standard treatment to see if it's safe and how well it helps prevent the body from rejecting the new kidney.
For: Renal TransplantationSweden · Spain · Austria - Ongoing, recruitingTherapeutic use (Phase IV)
The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction
This study for people with a type of heart failure called 'heart failure with preserved ejection fraction' is looking at how a medicine called empagliflozin affects tiny blood vessels in the skin. We want to see if it improves blood flow.
For: Heart failure with preserved ejection fractionNetherlands